Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 304.7 DKK -1.58%
Market Cap: 1.4T DKK

Novo Nordisk A/S
Accounts Payable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novo Nordisk A/S
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Accounts Payable
kr23.9B
CAGR 3-Years
42%
CAGR 5-Years
31%
CAGR 10-Years
20%
H Lundbeck A/S
CSE:HLUN A
Accounts Payable
kr4.4B
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Accounts Payable
kr113m
CAGR 3-Years
-3%
CAGR 5-Years
1%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Accounts Payable
kr2.6m
CAGR 3-Years
30%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
HIDDEN
Show

See Also

What is Novo Nordisk A/S's Accounts Payable?
Accounts Payable
23.9B DKK

Based on the financial report for Sep 30, 2025, Novo Nordisk A/S's Accounts Payable amounts to 23.9B DKK.

What is Novo Nordisk A/S's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
20%

Over the last year, the Accounts Payable growth was -1%. The average annual Accounts Payable growth rates for Novo Nordisk A/S have been 42% over the past three years , 31% over the past five years , and 20% over the past ten years .

Back to Top